150 related articles for article (PubMed ID: 36962909)
1. Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis.
Sweeney S; Berry C; Kazounis E; Motta I; Vassall A; Dodd M; Fielding K; Nyang'wa BT
PLOS Glob Public Health; 2022; 2(12):e0001337. PubMed ID: 36962909
[TBL] [Abstract][Full Text] [Related]
2. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
James LP; Klaassen F; Sweeney S; Furin J; Franke MF; Yaesoubi R; Chesov D; Ciobanu N; Codreanu A; Crudu V; Cohen T; Menzies NA
PLoS Med; 2024 May; 21(5):e1004401. PubMed ID: 38701084
[TBL] [Abstract][Full Text] [Related]
3. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Moodliar R; Dodd M; Solodovnikova V; Liverko I; Rajaram S; Rassool M; McHugh T; Spigelman M; Moore DA; Ritmeijer K; du Cros P; Fielding K;
Lancet Respir Med; 2024 Feb; 12(2):117-128. PubMed ID: 37980911
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
Gomez GB; Siapka M; Conradie F; Ndjeka N; Garfin AMC; Lomtadze N; Avaliani Z; Kiria N; Malhotra S; Cook-Scalise S; Juneja S; Everitt D; Spigelman M; Vassall A
BMJ Open; 2021 Dec; 11(12):e051521. PubMed ID: 34862287
[TBL] [Abstract][Full Text] [Related]
5. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
6. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
Günther G; Guglielmetti L; Kherabi Y; Duarte R; Lange C;
Clin Microbiol Infect; 2024 Mar; ():. PubMed ID: 38490355
[TBL] [Abstract][Full Text] [Related]
7. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.
Hasan T; Medcalf E; Nyang'wa BT; Egizi E; Berry C; Dodd M; Foraida S; Gegia M; Li M; Mirzayev F; Morgan H; Motta I; Nguyen L; Schumacher S; Schlub T; Fox G
Clin Infect Dis; 2024 Mar; 78(3):730-741. PubMed ID: 37874021
[TBL] [Abstract][Full Text] [Related]
8. Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis.
Mulder C; Rupert S; Setiawan E; Mambetova E; Edo P; Sugiharto J; Useni S; Malhotra S; Cook-Scalise S; Pambudi I; Kadyrov A; Lawanson A; van den Hof S; Gebhard A; Juneja S; Sohn H
BMJ Glob Health; 2022 Jan; 7(1):. PubMed ID: 34992077
[TBL] [Abstract][Full Text] [Related]
9. How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
Motta I; Cusinato M; Ludman AJ; Lachenal N; Dodd M; Soe M; Abdrasuliev T; Usmanova R; Butabekov I; Nikolaevna TZ; Liverko I; Parpieva N; Moodliar R; Solodovnikova V; Kazounis E; Nyang'wa B-T; Fielding KL; Berry C
Antimicrob Agents Chemother; 2024 Jun; ():e0053624. PubMed ID: 38842323
[TBL] [Abstract][Full Text] [Related]
10. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
Nsengiyumva NP; Campbell JR; Oxlade O; Vesga JF; Lienhardt C; Trajman A; Falzon D; Den Boon S; Arinaminpathy N; Schwartzman K
PLoS Med; 2022 Jun; 19(6):e1004032. PubMed ID: 35696431
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
[No Abstract] [Full Text] [Related]
12. Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial.
Rosu L; Madan JJ; Tomeny EM; Muniyandi M; Nidoi J; Girma M; Vilc V; Bindroo P; Dhandhukiya R; Bayissa AK; Meressa D; Narendran G; Solanki R; Bhatnagar AK; Tudor E; Kirenga B; Meredith SK; Nunn AJ; Bronson G; Rusen ID; Squire SB; Worrall E;
Lancet Glob Health; 2023 Feb; 11(2):e265-e277. PubMed ID: 36565704
[TBL] [Abstract][Full Text] [Related]
13. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
[TBL] [Abstract][Full Text] [Related]
14. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
Schnippel K; Firnhaber C; Page-Shipp L; Sinanovic E
Int J Tuberc Lung Dis; 2018 Aug; 22(8):918-925. PubMed ID: 29991402
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of pretomanid-based regimen for highly drugresistant TB in a low-burden setting.
Fekadu G; Wang Y; You JHS
Int J Tuberc Lung Dis; 2024 Feb; 28(2):81-85. PubMed ID: 38303041
[No Abstract] [Full Text] [Related]
16. Bedaquiline-based treatment for extensively drug-resistant tuberculosis in South Africa: A cost-effectiveness analysis.
Fekadu G; Yao J; You JHS
PLoS One; 2022; 17(8):e0272770. PubMed ID: 35930574
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
18. Relapse after treatment with standardized all-oral short regimens for rifampicin-resistant tuberculosis (RR-TB): A systematic review and
Reza Yosofi A; Mesic A; Decroo T
J Clin Tuberc Other Mycobact Dis; 2024 May; 35():100426. PubMed ID: 38468818
[TBL] [Abstract][Full Text] [Related]
19. Global adoption of 6-month drug-resistant TB regimens: Projected uptake by 2026.
Gupta A; Juneja S; Babawale V; Rustam Majidovich N; Ndjeka N; Thi Mai Nguyen P; Nargiza Nusratovna P; Robert Omanito D; Tiara Pakasi T; Terleeva Y; Toktogonova A; Waheed Y; Myint Z; Yanlin Z; Sahu S
PLoS One; 2024; 19(1):e0296448. PubMed ID: 38180980
[TBL] [Abstract][Full Text] [Related]
20. A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides.
Ali MZ; Dutt TS; MacNeill A; Walz A; Pearce C; Lam H; Philp J; Patterson J; Henao-Tamayo M; Lee RE; Liu J; Robertson GT; Hickey AJ; Meibohm B; Gonzalez-Juarrero M
bioRxiv; 2024 Jun; ():. PubMed ID: 38014249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
